Hair loss treatment has changed more in the last five years than in the previous twenty. Here’s what the peer-reviewed literature actually says about every therapy on our menu — what’s well-proven, what’s promising, and where we’re honest about the limits.
How to read this page. Each treatment is rated by the strength of the evidence behind it: Strong (multiple randomized trials and meta-analyses), Moderate (smaller trials and consistent observational data), or Emerging (early but high-quality clinical data). For each, you’ll see a plain-language summary up top and the clinical detail underneath. Citations are numbered and listed at the end.
Regenerative Biologics
Platelet-Rich Plasma (PRP)
Strong evidence · Level I
PRP is the most-studied regenerative therapy for hair loss. Your own platelets are concentrated and injected into the scalp, where they release growth factors that wake dormant follicles, thicken existing hairs, and improve scalp health. Multiple meta-analyses through 2025 show meaningful gains in hair density and shaft thickness at 3 and 6 months.
CLINICAL DETAIL. A 2024 systematic review in the Journal of Cosmetic Dermatology (Donnelly et al., 23 RCTs) and a 2025 Dermatology and Therapy meta-analysis both confirm statistically significant density gains over placebo at 3 and 6 months [1,2]. Head-to-head trials show PRP density gains comparable to topical minoxidil, with combination therapy outperforming either alone [3]. A 2025 network meta-analysis ranked PRP + bFGF + minoxidil first among 20 combinations for overall efficacy (SUCRA 93%) [4].
Best for: early to moderate androgenetic alopecia, treatment-naïve patients, and partial responders to minoxidil. Protocol: 3–4 sessions four weeks apart, maintenance every 3–6 months.
Platelet-Rich Fibrin (PRF)
Moderate evidence · Level II
PRF is a next-generation cousin of PRP. The same blood draw is processed without anticoagulants, so it forms a fibrin matrix that releases growth factors slowly over 7–14 days — potentially longer-lasting follicle stimulation per session. We use it on its own or paired with PRP in our combination protocol.
CLINICAL DETAIL. Mechanistically, PRF’s sustained-release fibrin scaffold prolongs growth-factor exposure beyond what activated PRP delivers in a single bolus. Direct PRP-vs-PRF RCT data remains smaller in volume than PRP’s evidence base, but density and thickness outcomes in published head-to-head trials are comparable [5]. We offer PRF to patients who prefer an additive-free preparation or who plateau on PRP alone.
Protocol: 60–80 mL blood draw across 6–8 specialized tubes; 3–4 sessions four weeks apart.
Combination PRP + PRF
Moderate evidence · mechanism-based
Our most comprehensive biologic session: PRP for an immediate growth-factor surge plus PRF for sustained release over the following two weeks. Designed for patients who want the strongest single-visit biologic stack.
CLINICAL DETAIL. Rationale draws on the complementary release kinetics: activated PRP delivers growth factors within the first 24 hours; PRF’s fibrin matrix continues releasing PDGF, TGF-β, IGF-1, and VEGF over 7–14 days. We use this protocol for patients pursuing aggressive stacking, those with Norwood IV+ / Ludwig II–III, and partial responders to single-biologic series.
Exosomes
Emerging evidence · Level III
Exosomes are nano-sized cellular messengers that carry growth factors and signaling molecules. We deliver a medical-grade exosome product topically with microneedling — no blood draw required. The evidence base is newer than PRP, but the early signal is strong and growing.
CLINICAL DETAIL. A 2025 systematic review in Clinical, Cosmetic and Investigational Dermatology examined 11 clinical studies (2022–2025; RCTs, prospective and retrospective cohorts, case series; n = 1–85 per study) [6]. Mesenchymal stem cell-derived exosomes (adipose, placenta, hair follicle, bone marrow, umbilical cord) showed density gains of 9.5–35 hairs/cm² and shaft thickness gains up to 13 µm, with a strong safety profile across all studies. Protocols remain heterogeneous — we frame this as promising and growing, smaller and newer than PRP.
Protocol: 3 sessions four weeks apart with microneedling, maintenance every 12–18 months.
Platelet-Derived Growth Factor (PDGF)
Emerging evidence · mechanism-based
PDGF is one of the key signals that maintains the stem-cell pool at the base of your hair follicles. We deliver it topically with microneedling, often as an adjunct between PRP sessions for additional growth-factor exposure.
CLINICAL DETAIL. A 2017 npj Regenerative Medicine paper (Gonzalez et al., University of Calgary) demonstrated that PDGF signaling is required for hair follicle dermal stem cell self-renewal; PDGF deficiency progressively depletes the stem cell pool [7]. Small clinical series report density gains in the 30–40% range at 6 months, though large RCTs remain pending. We position PDGF as a growth-factor adjunct, not a replacement for PRP.
Protocol: 3 sessions four weeks apart with microneedling, maintenance every 6–12 months.
Medical Therapies (The Foundation)
Topical Minoxidil
Strong evidence · Level I · FDA-approved
The most-studied topical for hair loss, FDA-approved since the 1980s. It improves scalp blood flow and prolongs the active growth phase of the hair cycle. Most patients see early changes around 8–12 weeks, with the largest gains between months 4 and 6.
CLINICAL DETAIL. Decades of RCT data establish topical minoxidil 2% and 5% as effective for male and female pattern hair loss, with dose-dependent response. Onset 8–12 weeks; maximum effect 4–6 months. An initial shedding phase in weeks 1–4 is expected and reflects synchronized cycling of telogen follicles into anagen. Discontinuation reliably leads to regression to baseline within 4–6 months.
Topical Finasteride
Strong evidence · Level I (recent)
A newer formulation of an old DHT-blocking medication. Applied directly to the scalp, it works at the follicle while delivering far lower systemic exposure than the oral pill, which means a much lower side-effect profile. Strong evidence when combined with topical minoxidil.
CLINICAL DETAIL. A 2024 prospective, randomized, controlled, assessor-blinded 3-arm trial in the Journal of Cosmetic Dermatology (Rossi et al.) demonstrated that topical minoxidil + topical finasteride 2.2 mg/mL outperformed either monotherapy in men with AGA [8]. A 2025 meta-analysis of minoxidil-finasteride mixed solutions confirmed superiority of the combination over minoxidil alone [9]. Systemic absorption with the topical is markedly lower than oral, reducing — though not eliminating — the risk of sexual or mood-related side effects.
Low-Dose Oral Minoxidil
Strong evidence · Level I (2024–2025 data)
A small once-daily pill (typically 1–5 mg for men, 0.5–1 mg for women) that has rapidly become a first-line option. A 2025 meta-analysis of nearly 3,000 patients found efficacy comparable to topical minoxidil with the convenience of a pill. We screen for blood pressure and heart history first.
CLINICAL DETAIL. A 2025 Frontiers in Pharmacology meta-analysis pooled 17 single-arm studies and 10 RCTs (n = 2,933) and demonstrated efficacy comparable to topical minoxidil with favorable tolerability: adverse-event odds ratio 0.27, hypertrichosis rate 0.35, lower-limb edema rate 0.04, treatment discontinuation 2.79% [10]. A 2024 head-to-head RCT in JAMA Dermatology (Vañó-Galván et al.) found oral minoxidil 5 mg once daily non-inferior to topical minoxidil 5% twice daily in male AGA [11]. Effusion and tamponade risk is rare at doses ≤5 mg.
Oral Finasteride & Dutasteride (Men)
Strong evidence · Level I
DHT-blockers taken as a daily pill. Finasteride 1 mg is FDA-approved for male pattern hair loss; dutasteride 0.5 mg is off-label but appears more effective in head-to-head studies. Side effects are uncommon but warrant a real conversation before starting.
CLINICAL DETAIL. Head-to-head meta-analysis demonstrates dutasteride 0.5 mg/day produces greater total hair count gains than finasteride 1 mg/day at 24 weeks, with comparable adverse-event rates [12]. Sexual side effects (decreased libido, erectile dysfunction) occur in 1–4% of patients in pooled trials and are usually reversible on discontinuation; we counsel honestly and screen for risk factors. Both agents are contraindicated in patients planning fatherhood without an appropriate washout.
Spironolactone (Women)
Strong evidence · Level I/II (premenopausal women)
An anti-androgen that blocks the effect of DHT at the follicle. Best evidence is in premenopausal women with female-pattern loss at 100–200 mg/day, often combined with topical or oral minoxidil for an additive effect. We monitor blood pressure and potassium.
CLINICAL DETAIL. A 2023 systematic review and meta-analysis (Wang et al.) found an overall response rate of 56.6% for oral spironolactone in female pattern hair loss, with the combination of spironolactone + minoxidil yielding 65.8% improvement versus 43.2% for monotherapy [13]. Adverse events reported in two or more studies: scalp pruritus 18.9%, menstrual irregularity 11.9%, facial hypertrichosis 6.9%, discontinuation 2.8%.
Adjunctive Therapies
Microneedling
Strong evidence as combination therapy · Level I
Controlled microchannels in the scalp open pathways for topical actives (minoxidil, PRP, exosomes, PDGF) and trigger a wound-healing response that can stimulate follicles on its own. The combination of microneedling and minoxidil consistently outperforms minoxidil alone, with faster onset.
CLINICAL DETAIL. A 2024 meta-analysis of 12 RCTs (n = 631; Pei et al., Journal of Cosmetic Dermatology) found microneedling combined with minoxidil produced significantly greater hair count gains than minoxidil alone (SMD 1.32, 95% CI 0.73–1.92, p < 0.01) [14]. Onset of visible response was earlier with combination therapy (approximately 6 weeks versus 10). A 2025 Frontiers network meta-analysis ranked microneedling + minoxidil as the most effective combination for female AGA (SUCRA 87%) [4].
Low-Level Light Therapy (LLLT)
Moderate evidence · FDA-cleared devices
FDA-cleared at-home and in-clinic devices that use red light to stimulate the scalp. Painless, no downtime. Bigger effects show up after about 20 weeks of consistent use — adherence is the key variable.
CLINICAL DETAIL. A 2024 meta-analysis of 38 studies (n = 3,098; 2,930 with androgenetic alopecia) found LLLT significantly increased hair density versus placebo (SMD 1.32, 95% CI 0.93–1.71, p < 0.001) [15]. Effect size was larger after 20 weeks of treatment (SMD 1.44) than before (SMD 1.14). LLLT pairs well with topical minoxidil and is a good option for patients who decline injections or want to maintain results between in-clinic sessions.
Nutraceuticals (Nutrafol)
Moderate evidence (brand-specific RCTs)
Targeted supplements that address some of the underlying contributors to thinning — stress hormones, micronutrient gaps, and inflammation. They work best alongside medical and biologic therapies, not instead of them.
CLINICAL DETAIL. Brand-specific RCTs for Nutrafol have shown improvements in hair growth, thickness, and shedding versus placebo at 3 and 6 months in women with self-perceived thinning. We use nutraceuticals as part of a stacked plan rather than as standalone treatment, and we recommend checking certain labs such as ferritin, vitamin D, B12, thyroid, and hormones for the best customized approach.
Why We Stack
No single treatment is the answer for hair loss. The strongest real-world results come from combining therapies that work at different points in the hair growth cycle — DHT blockade plus circulation support plus regenerative biologics plus microneedling for absorption. Network meta-analyses consistently show that combination therapy outperforms any monotherapy, often by a wide margin [4]. Your plan is built around what’s driving your loss, not a single product.
How we keep ourselves honest. We re-photograph at 3 and 6 months and review the images with you. If a treatment isn’t working, we say so and change the plan. Hair restoration isn’t a sales pitch — it’s a series of evidence-based decisions reviewed on a real timeline.
References
- Donnelly K, et al. The role of platelet-rich plasma in androgenetic alopecia: A systematic review. Journal of Cosmetic Dermatology, 2024. doi:10.1111/jocd.16185
- Platelet-Rich Plasma in the Management of Alopecia: A Systematic Review and Meta-Analysis of Clinical Evidence. Dermatology and Therapy, 2025. doi:10.1007/s13555-025-01542-8
- Comparison of the efficacy of platelet-rich plasma with topical minoxidil in treating patients with androgenetic alopecia: a systematic review of clinical trials. Skin Health and Disease, 2025;5(5):311. Skin Health and Disease
- Relative efficacy of minoxidil in combination with other treatments for androgenic alopecia: a network meta-analysis based on randomized controlled trials. Frontiers in Medicine, 2025. doi:10.3389/fmed.2025.1638496
- Shrestha K, et al. Platelet-rich fibrin: A review of its role as a new treatment in androgenetic alopecia. Journal of Cosmetic Dermatology, 2024. doi:10.1111/jocd.16333
- Exosomes and Hair Regeneration: A Systematic Review of Clinical Evidence Across Alopecia Types and Exosome Sources. Clinical, Cosmetic and Investigational Dermatology, 2025. doi:10.2147/CCID.S543451
- Gonzalez R, Moffatt G, Biernaskie J, et al. Platelet-derived growth factor signaling modulates adult hair follicle dermal stem cell maintenance and self-renewal. npj Regenerative Medicine, 2017. doi:10.1038/s41536-017-0013-4
- Rossi A, et al. Efficacy of the association of topical minoxidil and topical finasteride compared to their use in monotherapy in men with androgenetic alopecia: A prospective, randomized, controlled, assessor-blinded, 3-arm, pilot trial. Journal of Cosmetic Dermatology, 2024. doi:10.1111/jocd.15953
- Comparing minoxidil-finasteride mixed solution with minoxidil solution alone for male androgenetic alopecia: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Medicine, 2025. doi:10.3389/fmed.2025.1632139
- Efficacy and safety of oral minoxidil in the treatment of alopecia: a single-arm rate meta-analysis and systematic review. Frontiers in Pharmacology, 2025 (n = 2,933). PMC12188453
- Vañó-Galván S, et al. Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial. JAMA Dermatology, 2024. JAMA Dermatology
- Zhou Z, et al. The efficacy and safety of dutasteride compared with finasteride in treating men with androgenetic alopecia: a systematic review and meta-analysis. Clinical Interventions in Aging, 2019 (3 studies, n = 576). doi:10.2147/CIA.S192435
- Wang C, et al. The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis. 2023. PMC10502763
- Pei J, et al. Efficacy and safety of combined microneedling therapy for androgenic alopecia: A systematic review and meta-analysis of randomized clinical trials. Journal of Cosmetic Dermatology, 2024 (12 RCTs, n = 631). doi:10.1111/jocd.16186
- Low-Level Laser and LED Therapy in Alopecia: A Systematic Review and Meta-Analysis (n = 3,098). Dermatologic Surgery, 2024. PubMed 39404126
Disclaimer. This page summarizes the peer-reviewed evidence for therapies offered at Nervana Medical. It is not medical advice and does not replace a clinical consultation. Individual response varies. Some therapies described are not FDA-approved for hair restoration and are used off-label; this is legal, common in dermatology and aesthetic medicine, and does not imply experimental status. Last reviewed: May 2026.